NKTR-255+cetuximab in patients with solid tumors: Interim safety and efficacy results from the phase 1b dose-escalation study

Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2021
This article has no abstract
Epistemonikos ID: 35a36ff5baa0ad00f1e54a497ceacb257b872bc1
First added on: Feb 13, 2025